Risk factor
Very high price volatility
Profitability factor
Greatly overvalued vs peers
About
TaiwanJ Pharmaceuticals Co., Ltd. operates as a specialized biotech firm dedicated to the research, development, and commercialization of small molecule therapeutics. Initially, its focus within Taiwan has been on tackling chronic organ inflammation stemming from metabolic, autoimmune, or infectious causes. The company's growing pipeline also features specific compounds like JKB-122 and JKB-121, alongside a collection of innovative chemical entities. These new drugs are being developed to address persistent liver conditions and allergic respiratory ailments, such as asthma. TaiwanJ's comprehensive product portfolio is engineered to combat a wide array of diseases, encompassing hepatic inflammation and fibrosis, non-alcoholic steatohepatitis (NASH), non-alcoholic fatty liver disease (NAFLD), various autoimmune disorders, asthma, and atopic dermatitis (eczema). Established in 2011, the company's operations are headquartered in Zhubei, Taiwan.
Company Valuation
Considering past and projected metrics, the stock is distinctly 'expensive' compared to its peers.